

SINGAPORE
2018

ESMO ASIA

ESMO
COLLOQUIA

IMMUNOTHERAPY OF LUNG CANCER: ALONE OR IN COMBINATION?

ROOM 311
SUNTEC, SINGAPORE

Chairs:

Tetsuya Mitsudomi, Japan
David Planchard, France

This educational activity is provided by ESMO
and supported by Lilly and Roche.

Lilly ONCOLOGY



FRIDAY, 23 NOVEMBER 2018
12:45 - 14:15

- 12:45 Introduction
Tetsuya Mitsudomi, Osaka, Japan
- 12:50 1st line immunotherapy options for patients
without an oncogene driver
Ross Soo, Singapore
- 13:10 What is the biological rationale for combining
chemotherapy with immune checkpoints
(ICPs) inhibitors?
Marina Garassino, Milan, Italy
- 13:30 Are ICPs better as single agent, doublet ICPs or
combined with chemo +/- anti-angiogenics?
Solange Peters, Lausanne, Switzerland
- 13:50 What's new in the guidelines for immune
therapy of metastatic NSCLC?
David Planchard, Villejuif, France
- 14:10 Conclusions
Tetsuya Mitsudomi, Osaka, Japan